Welcome to our dedicated page for Enhabit SEC filings (Ticker: EHAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enhabit, Inc. filings document formal disclosures for a public home health and hospice care provider. Recent reports include 8-K material-event disclosures, Regulation FD materials, operating and financial results, risk-factor updates, shareholder voting matters and capital-structure information.
The company’s SEC record also covers material definitive agreements, including credit facilities and related debt terms, governance matters such as officer transitions, and litigation-related disclosures involving claims connected to its home health and hospice business history. These filings frame Enhabit’s regulatory reporting around healthcare operations, financing arrangements, corporate governance and stockholder matters.
Enhabit, Inc. (EHAB) – Form 4 Insider Transaction
Director Charles M. Elson reported the acquisition of 2,579 common-stock deferred stock units on 10 Jul 2025 under the company’s Deferred Director Compensation Plan. The units were valued at $7.27 per share, representing roughly $18.8 thousand in equity received in lieu of a cash retainer. Following the award, Elson’s total direct beneficial ownership rises to 75,073 shares.
- Transaction code “A” denotes an award or grant, not an open-market purchase.
- The incremental increase is about 3.6 % versus Elson’s prior stake of roughly 72,494 shares.
- No derivative securities were involved in this filing.
The filing signals routine compensation rather than a discretionary purchase, so market impact is expected to be limited. However, growing insider ownership can be interpreted as modestly positive for alignment with shareholder interests.